- Home
- PHAR vs MLYS Comparison
PHAR vs MLYS Comparison
Compare PHAR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- MLYS
- Stock Information
- Founded
- PHAR 1988
- MLYS 2019
- Country
- PHAR Netherlands
- MLYS United States
- Employees
- PHAR N/A
- MLYS N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- MLYS Health Care
- Exchange
- PHAR Nasdaq
- MLYS Nasdaq
- Market Cap
- PHAR 1.0B
- MLYS 890.6M
- IPO Year
- PHAR N/A
- MLYS 2023
- Fundamental
- Price
- PHAR $14.27
- MLYS $37.42
- Analyst Decision
- PHAR Strong Buy
- MLYS Strong Buy
- Analyst Count
- PHAR 3
- MLYS 6
- Target Price
- PHAR $30.00
- MLYS $42.60
- AVG Volume (30 Days)
- PHAR 12.8K
- MLYS 2.6M
- Earning Date
- PHAR 10-23-2025
- MLYS 11-10-2025
- Dividend Yield
- PHAR N/A
- MLYS N/A
- EPS Growth
- PHAR N/A
- MLYS N/A
- EPS
- PHAR N/A
- MLYS N/A
- Revenue
- PHAR $339,836,000.00
- MLYS N/A
- Revenue This Year
- PHAR $16.63
- MLYS N/A
- Revenue Next Year
- PHAR $6.77
- MLYS N/A
- P/E Ratio
- PHAR N/A
- MLYS N/A
- Revenue Growth
- PHAR 22.44
- MLYS N/A
- 52 Week Low
- PHAR $7.31
- MLYS $8.24
- 52 Week High
- PHAR $17.08
- MLYS $39.20
- Technical
- Relative Strength Index (RSI)
- PHAR 54.65
- MLYS 83.46
- Support Level
- PHAR $13.63
- MLYS $34.59
- Resistance Level
- PHAR $15.61
- MLYS $39.20
- Average True Range (ATR)
- PHAR 0.93
- MLYS 2.76
- MACD
- PHAR -0.13
- MLYS 1.02
- Stochastic Oscillator
- PHAR 35.98
- MLYS 92.66
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.